

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Nanosonics Limited</b>
<b>ABN</b>	<b>11 095 076 896</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Michael Kavanagh
<b>Date of last notice</b>	15 September 2017

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	a) Indirect Interest b) Indirect Interest c) Indirect Interest d) Indirect Interest e) Direct Interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	a) Performance Rights held in the Nanosonics Employee Share Option Plan. b) Shares held under the Nanosonics Deferred Employee Share Plan (Trust) c) Performance Rights held in the Nanosonics Omnibus Equity Plan d) Options held in the Nanosonics Omnibus Equity Plan
<b>Date of change</b>	18 September 2017

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held prior to change</b>	a) 206,882 Performance Rights held in the Nanosonics Employee Share Option Plan. b) 1,618,540 (Indirect) Ordinary Shares c) 78,961 Performance Rights held in the Nanosonics Omnibus Equity Plan. d) 211,306 Options held in the Nanosonics Omnibus Equity Plan e) 150,000 (Direct) Ordinary Shares
<b>Class</b>	a) Performance Rights b) Ordinary Shares c) Performance Rights d) Options e) Ordinary shares
<b>Number acquired</b>	36,823 Ordinary Shares
<b>Number disposed</b>	36,823 Performance Rights held under the Nanosonics Omnibus Equity Plan.
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	N/A
<b>No. of securities held after change</b>	a) 206,882 Performance Rights held in the Nanosonics Employee Share Option Plan. b) 1,655,363 (Indirect) Ordinary Shares c) 42,138 Performance Rights held in the Nanosonics Omnibus Equity Plan. d) 211,306 Options held in the Nanosonics Omnibus Equity Plan e) 150,000 (Direct) Ordinary Shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of 36,823 Performance Rights under the terms and conditions of the Nanosonics Omnibus Equity Plan.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

Director: Mr. Michael Kavanagh  
Date: 18 September 2017

---

<sup>+</sup> See chapter 19 for defined terms.